Literature DB >> 24239320

Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.

Maen D Abou Ziki1, Yael Strulovici-Barel2, Neil R Hackett2, Juan L Rodriguez-Flores2, Jason G Mezey3, Jacqueline Salit2, Sharon Radisch2, Charleen Hollmann2, Lotfi Chouchane4, Joel Malek4, Mahmoud A Zirie5, Amin Jayyuosi5, Antonio M Gotto6, Ronald G Crystal7.   

Abstract

Apolipoprotein E, a protein component of blood lipid particles, plays an important role in lipid transport. Different mutations in the apolipoprotein E gene have been associated with various clinical phenotypes. In an initiated study of Qataris, we observed that 17% of the African-derived genetic subgroup were heterozygotes for a rare Arg145Cys (R145C) variant that functions as a dominant trait with incomplete penetrance associated with type III hyperlipoproteinemia. On the basis of this observation, we hypothesized that the R145C polymorphism might be common in African-derived populations. The prevalence of the R145C variant was assessed worldwide in the "1000 Genomes Project" and in 1,012 whites and 1,226 African-Americans in New York, New York. The 1000 Genomes Project data demonstrated that the R145C polymorphism is rare in non-African-derived populations but present in 5% to 12% of Sub-Saharan African-derived populations. The R145C polymorphism was also rare in New York whites (1 of 1,012, 0.1%); however, strikingly, 53 of the 1,226 New York African-Americans (4.3%) were R145C heterozygotes. The lipid profiles of the Qatari and New York R145C heterozygotes were compared with those of controls. The Qatari R145C subjects had higher triglyceride levels than the Qatari controls (p <0.007) and the New York African-American R145C subjects had an average of 52% greater fasting triglyceride levels than the New York African-American controls (p <0.002). From these observations, likely millions of people worldwide derived from Sub-Saharan Africans are apolipoprotein E R145C. In conclusion, although larger epidemiologic studies are necessary to determine the long-term consequences of this polymorphism, the available evidence suggests it is a common cause of a mild triglyceride dyslipidemia.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24239320      PMCID: PMC3943837          DOI: 10.1016/j.amjcard.2013.09.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

1.  Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia.

Authors:  P Lohse; W A Mann; E A Stein; H B Brewer
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

2.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 3.  The role of apolipoprotein E genetic variants in lipoprotein disorders.

Authors:  S C Rall; R W Mahley
Journal:  J Intern Med       Date:  1992-06       Impact factor: 8.989

4.  Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation.

Authors:  T Vogel; N H Guo; R Guy; N Drezlich; H C Krutzsch; D A Blake; A Panet; D D Roberts
Journal:  J Cell Biochem       Date:  1994-03       Impact factor: 4.429

5.  Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.

Authors:  P Lohse; D J Rader; H B Brewer
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

6.  Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.

Authors:  Z S Ji; S Fazio; R W Mahley
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

7.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

Review 8.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

Review 9.  Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease.

Authors:  R W Mahley
Journal:  Isr J Med Sci       Date:  1996-06

10.  Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary.

Authors:  M J Mistry; M A Clay; M E Kelly; M A Steiner; J A Harmony
Journal:  Cell Immunol       Date:  1995-01       Impact factor: 4.868

View more
  2 in total

1.  Rare mutation in the SLC26A3 transporter causes life-long diarrhoea with metabolic alkalosis.

Authors:  Maen D Abou Ziki; Mohamud A Verjee
Journal:  BMJ Case Rep       Date:  2015-01-07

Review 2.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.